Skip to main content
Journal cover image

Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer.

Publication ,  Journal Article
Troy, JD; Weissfeld, JL; Diergaarde, B; Youk, AO; Buch, SC; Romkes, M; Grandis, JR
Published in: Cancer Epidemiol
August 2013

INTRODUCTION: Functional polymorphisms in drug metabolizing enzymes (DMEs) may be determinants of survival in oral and oropharyngeal squamous cell carcinoma (OOSCC). METHODS: OOSCC cases (N=159) with a history of either tobacco or alcohol use were genotyped for polymorphisms in eight DMEs. Overall and disease-specific survival were analyzed using Kaplan-Meier plots and the log-rank test. Cox proportional hazards regression was used to calculate hazard ratios (HR) and 95% confidence intervals (CI) in exploratory analyses of patient subgroups. RESULTS: Kaplan-Meier analyses showed N-acteyltransferase-2 (NAT2) fast acetylators experienced a 19.7% higher 5-year survival rate than slow acetylators (P=0.03) and this association was similar in oropharyngeal and oral cancer. After multiple adjustment, including tumor site and stage, the NAT2 fast acetylator phenotype was associated with improved overall survival (vs. slow acetylators) provided chemotherapy or radiation were not used (HR, 0.26; 95% CI, 0.10-0.66). However, NAT2 phenotype was unrelated to survival in patients treated with chemoradiotherapy (HR, 1.21; 95% CI, 0.54-2.73) or radiotherapy (HR, 0.67; 95% CI, 0.31-1.59) (P-for-NAT2/treatment-interaction=0.04). Normal activity GSTP1 was associated with a 19.2% reduction in 5-year disease-specific survival relative to reduced activity GSTP1 (P=0.04) but this association was not modified by treatment. CONCLUSIONS: Our results suggest that functional polymorphisms in NAT2 and GSTP1 are associated with OOSCC survival. Confirmation of these results in larger studies is required.

Duke Scholars

Published In

Cancer Epidemiol

DOI

EISSN

1877-783X

Publication Date

August 2013

Volume

37

Issue

4

Start / End Page

505 / 511

Location

Netherlands

Related Subject Headings

  • Survival Rate
  • Smoking
  • Proportional Hazards Models
  • Polymorphism, Single Nucleotide
  • Phenotype
  • Oropharyngeal Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Mouth Neoplasms
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Troy, J. D., Weissfeld, J. L., Diergaarde, B., Youk, A. O., Buch, S. C., Romkes, M., & Grandis, J. R. (2013). Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer. Cancer Epidemiol, 37(4), 505–511. https://doi.org/10.1016/j.canep.2013.02.009
Troy, Jesse D., Joel L. Weissfeld, Brenda Diergaarde, Ada O. Youk, Shama C. Buch, Marjorie Romkes, and Jennifer R. Grandis. “Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer.Cancer Epidemiol 37, no. 4 (August 2013): 505–11. https://doi.org/10.1016/j.canep.2013.02.009.
Troy JD, Weissfeld JL, Diergaarde B, Youk AO, Buch SC, Romkes M, et al. Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer. Cancer Epidemiol. 2013 Aug;37(4):505–11.
Troy, Jesse D., et al. “Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer.Cancer Epidemiol, vol. 37, no. 4, Aug. 2013, pp. 505–11. Pubmed, doi:10.1016/j.canep.2013.02.009.
Troy JD, Weissfeld JL, Diergaarde B, Youk AO, Buch SC, Romkes M, Grandis JR. Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer. Cancer Epidemiol. 2013 Aug;37(4):505–511.
Journal cover image

Published In

Cancer Epidemiol

DOI

EISSN

1877-783X

Publication Date

August 2013

Volume

37

Issue

4

Start / End Page

505 / 511

Location

Netherlands

Related Subject Headings

  • Survival Rate
  • Smoking
  • Proportional Hazards Models
  • Polymorphism, Single Nucleotide
  • Phenotype
  • Oropharyngeal Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Mouth Neoplasms
  • Middle Aged